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 This work was presented as “Neutropenia febril en el trópico: descripción de hallazgos clínicos, microbiológicos y 
desenlace en un centro de referencia oncológico” at the XIX Congreso Colombiano de  Medicina Interna, 
 Cartagena, Colombia, 16 a 19 de octubre de 2006. 
Introduction. Febrile neutropenia is a common complication of chemotherapy treatment of malignant 
hematological diseases. However, there is insufficient information regarding the infectious complications 
of febrile neutropenia in our country.
Objective. We will evaluate the microbial characteristics of bacterial and fungal isolates and the clinical 
outcome of patients with febrile neutropenia who received medical attention at an oncological reference 
center in Colombia.
Materials and methods. A prospective case series included patients with histologically confirmed 
oncological disease, who were admitted because of febrile neutropenia or presented with febrile 
neutropenia during hospitalization. Patients with benign hematological diseases were excluded. 
Demographic, microbiological, and clinical features as well as treatment and outcome information from 
patients with febrile neutropenia were obtained. We performed univariate and multivariate analyses, 
with mortality defined as the outcome.
Results. One hundred and thirty episodes of febrile neutropenia were identified in 104 patients. The 
mean patient age was 19, and 53% of the patients were male. Approximately 86% of the episodes 
occurred in patients with hematological disorders. An infectious site was identified in 65% of patients; 
41% and 24% of the febrile neutropenia pateints´ episodes exhibited a localized infectious focus and 
developed bloodstream infections, respectively. The majority of infections were found in blood, urine, 
gastrointestinal tract, and soft tissue. Distribution analysis of microbiological isolates revealed 46.4% 
Gram-negative bacilli, 38.4% Gram-positive cocci, 8% fungi, and 7.1% parasites; there was a 7.7% 
mortality rate. Appropriate empirical antimicrobial therapy was a protection-related factor in multivariate 
analyses (OR= 0.17; 0.034 – 0.9 95% CI; p= 0.037). 
Conclusions. The mortality rate was relatively low and comparable to the rate reported by developed 
countries. Inappropriate empirical antimicrobial therapy was the main factor associated with mortality. 
Keywords: Neutropenia/microbiology, neutropenia/mortality, neoplasm/complications, antineoplastic 
agents/adverse events, Colombia. 
doi: http://dx.doi.org/10.7705/biomedica.v32i4.750
Neutropenia febril en el trópico: una descripción de los hallazgos clínicos y microbiológicos 
y el impacto de la terapia inapropiada que utilizan en un centro de referencia oncológica en 
Colombia
Introducción. La neutropenia febril es una complicación frecuente de la quimioterapia para las neoplasias 
hematológicas. Se dispone de escasa información de sus complicaciones infecciosas en nuestro medio.
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Objetivo. Evaluar las características clínicas y microbiológicas de pacientes con neutropenia febril, así 
como su resultado clínico en una institución de referencia oncológica en Colombia.
Materiales y métodos. Se conformó prospectivamente una serie de casos con pacientes con 
enfermedad oncológica confirmada, que consultaron o presentaron neutropenia febril durante la 
hospitalización. Se excluyeron aquellos con enfermedad hematológica benigna. Se recolectaron datos 
sobre variables demográficas, microbiológicas, clínicas, de tratamiento y de resultado de los pacientes. 
Se llevaron a cabo un análisis univariado y uno multivariado, con la mortalidad como resultado.
Resultados. Se identificaron 130 episodios de neutropenia febril en 104 pacientes, con una edad 
media de 19 años y 53 % masculinos. El 86 % de los episodios ocurrieron en pacientes con alteraciones 
hematológicas. Se demostró infección en 65 % de los casos: 41 % con un foco infeccioso localizado 
y 27,7 % con bacteriemia. Los principales focos infecciosos se localizaron en el torrente sanguíneo, 
el aparato urinario, el sistema gastrointestinal, la piel y los tejidos blandos. De los aislamientos 
microbiológicos, 46,4 % fueron bacilos Gram negativos, 38,4 %, cocos Gram positivos, 9 %, hongos 
y, 7,1%, parásitos. La mortalidad global fue de 7,7 %. En el análisis multivariado la utilización de un 
tratamiento empírico apropiado se correlacionó con una menor mortalidad, de forma independiente 
(OR=0,17; IC95% 0,034-0,9; p=0,037).
Conclusiones. La tasa de mortalidad fue relativamente baja y fue comparable con lo reportado en 
países desarrollados. El tratamiento antimicrobiano inapropiado fue el principal factor asociado con 
mortalidad.
Palabras clave: neutropenia/microbiología, neutropenia/mortalidad, neoplasias/complicaciones, 
antineoplásicos/efectos adversos, Colombia 
doi: http://dx.doi.org/10.7705/biomedica.v32i4.750
Approximately 50% of febrile neutropenic patients 
have an established or developing infection, 
whereas 20% of patients with a neutrophil count 
of less than 100 cells per milliliter have established 
bacteremia (1). The risk of death associated with 
febrile neutropenia (FN) has been considerably 
reduced during the last few years due to advances in 
diagnostic methods and broad-spectrum antibiotic 
therapies. Mortality over a 30-day period currently 
ranges from 6% to 10% among patients suffering 
from FN and bacteremia (2).
The clinical outcome for a patient suffering 
from FN is dependent on several factors; these 
include the patient’s underlying disease, age, 
clinical condition at the beginning of the clinical 
picture, number of infectious foci present, 
duration of the neutropenia, onset of antibiotic 
or antifungal therapy, geographical location and 
local antimicrobial resistance profiles (3). These 
antimicrobial resistance profiles have gained 
importance, as these patients are at risk of 
acquiring community or nosocomial infections. 
The microbiological findings offer valuable 
information about the most frequent etiological 
agents, antimicrobial resistance profiles, and the 
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prevalence of the least frequent microbiological 
isolates. The clinical findings based on exhaustive 
physical examinations guide diagnostic and 
therapeutic efforts aimed at identifying non-
apparent infectious foci. 
A series of prospective studies carried out in 
an oncological reference center in Colombia 
is presented. Our study evaluated clinical and 
microbiological findings, treatment, and important 
clinical outcomes for patients suffering from cancer 
and FN.
Materials and methods
Population: We studied a series of prospective 
cases from February to August 2003, which included 
patients who were admitted because of FN or were 
hospitalized at the moment of the identification of 
FN at the Instituto Nacional de Cancerologia in 
Bogotá, Colombia. 
Inclusion criteria: We accepted patients of all 
ages diagnosed with oncological disease who were 
confirmed by histology and who met the criteria for 
FN at admission or during hospitalization.
Exclusion criteria: Patients suffering from FN who 
had not received chemotherapy or showed benign 
hematological pathology were excluded.
Procedure: Potential patients were identified by 
hemograms in the hematology laboratory. An active 
search identified patients suffering from FN, and 
clinical histories were gathered from medical records 
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after patients with FN were identified. Information 
included demographic data, clinical diagnosis, risk 
factors present at the onset of neutropenia, such 
as invasive devices and prolonged hospital stay, 
state of oncological disease at the occurrence of 
neutropenia, and FN severity.
Data such as clinical manifestations, infectious foci 
present, microbiological findings, and empirical 
antibiotic therapy were collected at the time of FN 
diagnosis. The patients were followed during the 
FN period. Differences in neutropenia duration, 
changes in microbiological findings, antibiotic 
therapy adjustment, neutropenia resolution, and 
the patient’s state at the time of discharge were 
also recorded.
Microbiological information was obtained from the 
institution’s microbiology laboratory. Hemocultures 
and urocultures were routinely collected at the time 
of admission to the emergency room or following 
FN diagnosis. Other samples were collected if 
the attending physician considered it necessary 
during the patient’s hospitalization. All isolates 
were processed and identified using automated 
identification cards (MicroScan, Dade Behring, 
USA). Interpretations were made according to 
Clinical and Laboratory Standards Institute (CLSI)’s 
criteria (2005).
Definitions: A definition of neutropenia included an 
absolute neutrophil count of less than 500 cells per 
milliliter or less than 1,000 cells per milliliter with 
a downward trend over time. Fever was defined 
as a single measurement of auxiliary temperature 
greater than 38.3ºC or greater than 38ºC for more 
than one hour. State of base disease: Active or in 
remission. FN severity: severe: absolute neutrophil 
count (ANC): ≤ 100 cell/ml. Slight-moderate: ANC 
>100 cell/ml and ≤1 000 cell/ml or a decreasing 
tendency. 
The following definitions were taken into account 
when classifying patients according to infection 
focus. Clinical sepsis: a systemic inflammatory 
response syndrome without clinical or microbiological 
findings, revealing an infectious focus. Local 
focus: local infection as evidenced by clinical or 
microbiological findings without dissemination 
into the bloodstream. Primary bacteremia: a 
microbiological isolate from the bloodstream without 
documentation of any other local focus of infection. 
Secondary bacteremia: microbiological isolate from 
the bloodstream concomitant with a microbiological 
isolate or clinical findings regarding local infection. 
Appropriate empirical antibiotic therapy: suitable 
antibiotic coverage for 72 hours following the 
identification of a microbiological isolate with 
identified suceptibility. Prolonged hospital stay: an 
in-hospital stay longer than 7 days.
Clinical management: At the time of the study, 
rutine antimicrobial prophylaxis was not used 
among neutropenic patient or patients receiving 
chemotherapy. Empirical treatment for patients with 
febrile neutropenia included cefepime or piperacillin-
tazobactam, as first line. Patients with persistent 
fever were started on meropenem and antifungal 
therapy was added. Antimicrobial adjustment was 
performed when appropiate cultures showed a 
causative microorganism.
Statistical analysis: Data were processed using 
SPSS software (version 11.5). P values were 
calculated using Fischer’s exact test for discrete 
variables and Student’s test for continuous 
variables. Variables with a p value ≤ 0.1 for 
univariate analysis were included in a multivariable 
logistical regression model with mortality outcome.
Ethical considerations
This is an observational study using data from 
medical records and laboratory findings collected 
from an institutional program with patients diagnosed 
with FN. No ethical approval was required.
Results
A total of 130 episodes of fever were identified in 
104 neutropenic patients during the study period. 
Patients’ age ranged from 6 months to 75 years 
(average age of 19 years). Fifty-five (53%) patients 
were male. Eighty-nine patients (85.6%) presented 
with hematological neoplasia as the underlying 
oncological disease. Seventy-eight (75%) patients 
presented with a single episode, 23 (22%) presented 
with 2 episodes, and 3 patients (3%) presented with 
3 episodes of FN.
The underlying oncological disease was active 
during 86 (66%) of FN episodes. FN was severe 
in 106 (81.5%) episodes. Prolonged hospital stay 
was associated with 41 (31.5%) episodes of FN. 
The average duration of neutropenia was 8 days, 
with a range of 2 to 42 days (table 1).
Infectious foci were identified in 85 (65%) of FN 
episodes. An infectious focus could not be identified 
in 45 (35%) episodes of FN, as those patients only 
presented signs of systemic inflammatory response 
syndrome (SIRS). At least one clear focus of infection 
was identified by clinical and/or microbiological 
procedures without confirmed bacteremia in 49 
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(37.7%) episodes of FN. Bloodstream infection, 
central venous catheter-associated bacteremia, 
primary bacteremia, and bacteremia with an 
infectious focus were documented in 36 cases 
(27.7%) (table 2).
The main infectious foci were bacteremia (27.7%), 
urinary tract infections (19%), gastrointestinal 
tract infections (19%), cellulitis (15%), oropharynx 
infections (mucositis and oral herpes) (12%), 
pneumonia (6%), and other foci (including sinusitis) 
representing less than 5%.
A total of 112 microbiological isolates were identified 
and included bacteria, fungi, and amoebas. These 
isolates included 52 Gram-negative bacilli (46.4%), 
43 Gram-positive cocci (38.4%), 9 fungi (8%) and 
8 Entamoeba histolytica/dispar (7.1%) (table 3). 
The most frequent isolate was Escherichia coli (21 
isolates in urine and 13 isolates in blood cultures), 
followed by Staphylococcus aureus (7 isolates 
in blood cultures) and Klebsiella pneumoniae 
(5 isolates in blood and 3 in urine cultures). 
Although 9 fungal isolates were identified, only 1 
isolate was identified in blood (Candida albicans) 
and one isolate in a skin biopsy (disseminated 
candidiasis); 6 isolates were detected in urine (C. 
albicans, C. tropicalis and other yeast), and one 
in a bronchoalveolar lavage, representing most 
likely colonization instead of truely infection. No 
filamentous fungi were identified. Microbiological 
isolate distribution changed over the course of 
an episode of febrile neutropenia; 79 (76%) of all 
microbiological isolates were collected during the 
first week of FN (Gram-negative bacilli represented 
48% of all isolates). E. histolytica isolates were 
detected during the first week of FN and were 
isolated from patients with diarrhea as the sole 
clinical symptom. Figure 1 shows the distribution 
of microbiological isolates during the course of FN.
Table 1. Description of patient population and its risk factors
Variable n (%)  (range)
Patients  104  (100) 
Episodes of febrile neutropenia 130  (100)
Gender
   Males  55  (53)
   Females 49  (47)
Average age (years) 19  (0.5-75)
Oncological diagnosis
Hematological 89  (86)
 Acute lymphoid leukemia  42  (48)
 Acute myeloid leukemia  27 (30)
 Non-Hodgkin’s lymphoma  12  (14)
 Hodgkin’s lymphoma 4  (5)
 Other hematological causes 4  (3)
Solid organ 15  (14)
 Osteosarcoma   (27)
 Breast cancer 2  (13)
 Ovarian cancer  2  (13)
 Other solid organs 7  (47)
State of disease at time of admission
 Active 86 (66)
 Remission 37  (29)
 Unknown 7  (5)
Average duration of neutropenia (days) 8  (2 - 42)
Prolonged hospital stay >1 week  41  (31.5)
Severity of febrile neutropenia (FN)
   Severe (ANC: < 100/µl) 106  (81.5)
   Slight- moderate (ANC: 100-500/µl)  24  (18.5)   
   (<1,000 cell/ul with tendency     
   toward reduction) 
Table 2 Distribution of clinical symptoms at time of FN diagnosis and their associated mortalities
Description of infectious foci Total of determined infectious foci  Mortality  p
  85/130 (65%) (%) 
Clinical sepsis without infectious foci 45  (35%) 2.2% (p=0.89)
Local infection 54  (41%)
 Urinary tract infection  19% 3.8% (p=0.164)
 Gastrointestinal infection (diarrhea)  19%
 Infection of the skin and soft tissues   15%
 Oral cavity (mucositis, herpes) infection  12%
 Pneumonia  6%
 Sinusitis  2.3%
 Other infectious foci   2.3%  
Bacteremia 36  (27.7%)
Catheter-associated infection 8  (6.1%) 0% (p=0.618)
Primary infection 10  (7.7%)  20.0% 
(p=0.128)
Secondary infection 18  (13.8%) 27.8% (P=0.01)*
* Compared with catheter-associated infection
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It is worth noting that an analysis of resistance 
profiles of Gram-negative bacilli during an FN 
episode revealed an increase in β-lactamase-
(ESBL) extended spectrum and meropenem-
mediated resistance among isolates during 
weeks 2, 3, and 4, compared with the first week. 
Resistance to third-generation cephalosporins in 
Gram-negative bacilli during the first week of FN 
was 26% and increased to 33% during weeks 2, 
3, and 4 (p=0.69). Meropenem-resistance was 
observed in 3% of isolates during the first week of 
FN and in 22% of isolates during weeks 2, 3, and 
4 (p=0.08). Eight percent of Gram-negative bacilli 
were resistant to quinolone. All Pseudomonas 
aeruginosa isolates were identified during the first 
week of FN. There was no difference in resistance 
profiles during the FN period among Gram-positive 
cocci, including S. aureus. Methicillin-resistant S. 
aureus represented 66% of S. aureus the isolates. 
No vancomycin-resistant microorganism was 
identified in this study.
Ten patients died from FN, which represents a 
7.7% mortality rate (deaths per episode); 50% of 
patients who died received inappropriate empirical 
antibiotic therapies compared with only 13% in 
surviving patients. 
Based on the univariate analysis, acquiring 
secondary bacteremia was associated with 
increased mortality (p=0.01), whereas receiving 
appropriate empirical antibiotic therapy was a 
mortality protection-related factor (p<0.001). In 
the multivariate analysis, receiving appropriate 
empirical antibiotic therapy was the sole significant 
variable that acted as a protection-related factor 
(OR= 0.17; 0.034–0.9 95%CI; p= 0.037).
Discussion
Febrile neutropenia is a frequent complication of 
chemotherapy, especially among patients diagnosed 
with malignant hematological disease. A significant 
percentage of FN episodes are associated with 
infection and infection is one of the main causes of 
mortality in cancer patients (2). The characteristics 
of microbiological isolates in FN patients have 
changed over the past 25 years, and Gram-positive 
cocci are currently the predominant group. This 
could be explained by the use of new antibiotics, 
the extended use of antibiotic prophylaxis, and 
increased invasive device-related infections (4-6).
Gram-negative bacilli (GNB), especially E. coli 
and other enterobacteria, constituted the most 
common group of isolates found among all the 
isolates identified and during the first week of 
FN. In contrast, studies from developed countries 
reported a predominance of Gram-positive cocci 
among FN isolates (7). We postulated that these 
differences are due to the absence of antibiotic 
prophylaxis in our setting. A previous study 
showed that administering antibiotic prophylaxis 
with levofloxacin to neutropenia patients following 
chemotherapy reduced the episodes of fever and 
bacteremia caused by GNB; no impact on mortality 
was evident (8). Data from Venezuela (9), Chile 
(10), and Taiwan (11) reflect a similar trend in the 
frequency of Gram-negative isolates.
It is an unusual finding that amoebas, which 
cause colitis and diarrhea, represented 8% of 
all microbiological isolates. This trend is usually 
observed in countries with high E. histolytica/dispar 
infection prevalence and has been previously 
described in cancer and immunosuppressed 
patients in our setting (12,13). E. histolytica/dispar 
infections were present during the first week of FN, 
suggesting that these infections are opportunistic. 
The accuracy of diagnosis (because Entamoeba 
is easily mistaken for blood-loaded macrophages) 
and the clinical impact of Entamoeba spp. findings 
are not clear.
The characterization of antibiotic resistance profiles 
revealed a trend toward increased meropenem- 
and ESBL-mediated resistance among GNB during 
FN. Although not statistically significant, this data 
indicate the emergence of resistance mechanisms 
against the first-line if antibiotics used to treat FN. 
Figure 1. Weekly distribution of microbiological 
isolates in 130 episodes of febrile neutropenia at 
a reference center in Colombia
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The high frequency in our data of GNB isolates 
resistant to third-generation cephalosporins is 
worth noting (28%). This finding has significant 
implications for other empirical antibiotic therapies 
(e.g., fourth-generation cefepime was used in our 
center at the time of the study). Although cefepime 
is not a strong ESBL inducer (in contrast to third-
generation cephalosporins), the high prevalence 
of GNB with ESBL indicates that improvements in 
isolation and infection control is essential to avoid 
the further spread of antibiotic resistance. Several 
studies have previously highlighted the implications 
of ESBL-carrier GNB isolates in patients with 
cancer and FN. GNB are characterized by the easy 
dissemination among patients in oncological units and 
their association with increased mortality (14,15).
Another important fact related to antibiotic 
resistance is the low rate of resistance to antibiotics 
rarely used for our patients with FN. Quinolone-
resistance was only observed in 8% of GNB isolates 
in our study. In contrast, the rates of resistance 
in other hospital units in Colombia, such as in 
intensive care units, varied between 22% and 31% 
over the past few years (16). The extended use of 
quinolones leads to the development of resistance 
in E. coli and S. epidermidis as well as the selection 
of methicillin-resistant Staphylococcus aureus 
(MRSA) (17,18). The role of antibiotic prophylaxis is 
still controversial because little is known regarding 
how long prophylaxis remains effective following its 
administration (i.e., there is currently no convincing 
evidence on the impact on antibiotic resistance 
rates among isolates from FN patients after several 
cycles of chemotherapy). Studies evaluating Gram-
positive resistance rates to the latest-generation 
quinolones (moxifloxacin and gatifloxacin) in 
patients with hematological disease who have been 
submitted to antibiotic prophylaxis with quinolones 
such as ciprofloxacin or levofloxacin, have shown 
selection of multi-resistant Gram-positives, such 
as MRSA and methicillin-resistant Staphylococcus 
epidermidis (MRSE) (19). These findings suggest 
an increase in and selection for multi-resistant 
Gram-positive isolates that are caused by the use 
of quinolones as antibiotic prophylaxes.
Pseudomonas aeruginosa infections are a major 
concern in immunosuppressed patients, as these 
patients have multiple risk factors that make them 
more susceptible to colonization and infection by 
this microorganism (20). Only 3% of the episodes 
in our study involved P. aeruginosa bacteraemia, 
all of which occurred during the first week of FN. 
This is a similar result to those reported by other 
studies (21). Maschmeyer, et al., reported that the 
Table 3 Microbiological isolates from patients with febrile neutropenia episodes 
Group of microorganism Species identified Number of isolates  Total isolates
   n (%) 
Gram-negative bacilli  Escherichia coli 24 52  (46.4) 
 Klebsiella pneumoniae 9  
 Pseudomonas aeruginosa 5  
 K. oxytoca 2    
 Stenotrophomonas maltophilia 2  
 Other Enterobacteriaceae* 5  
 Other Gram negatives** 5  
Gram-positive cocci  Staphylococcus aureus 9 43  (38.4) 
 S. epidermidis 8  
 Enterococcus faecalis 7  
 Streptococcus pneumoniae 5  
 S. mitis 3  
 E. faecium 3  
 Viridans streptococci 2   
 Other Gram-positive *** 6  
Fungi Candida albicans 4 9  (8)  
 C. tropicalis  3   
 Other yeasts**** 2  
Parasites E. histolytica/dispar  8 (7.1) 
Total   112  (100)
* Including isolates of Kluyvera ascorbata, Citrobacter spp., and Proteus spp. ** Including isolates of Acinetobacter spp., Aeromonas 
hydrophila, Chryseobacterium indologenes, and Pseudomonas spp. ***Including isolates of other coagulase negative Staphylococci, 
Leuconostoc spp., Enterococcus casseliflavus. ****Including one isolate of Saccharomyces cerevisiae and Rhodotorula rubra.
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prevalence of P. aeruginosa bacteremia is 5%-12% 
among patients with FN (20). Such findings establish 
P. aeruginosa as an infrequent microorganism in 
patients with cancer and FN, representing less than 
10% of the total isolates in previous studies
The absence of an appropriate empirical antibiotic 
therapy was the only risk factor associated with 
mortality in multivariate analysis. A recent study 
highlighted the relationship between the presence 
of bacteria with multiple resistance mechanisms and 
increased mortality when compared with isolates 
from multi-sensitive microorganisms. Increased 
mortality was related to the failure of empirical 
antibiotic therapy to provide suitable coverage 
against microorganisms with multiple resistance 
mechanisms (22). We thus found that initiating the 
appropriate empirical antibiotic therapy was the 
main protection-inducing factor against mortality in 
this study, which should be supported by findings 
from local resistance profiles.
Sixty percent of patients who died had not received 
appropriate empirical antibiotic-therapies. This 
fact highlights the importance of administering the 
appropriate antibiotics according to local resistance 
profiles and the patient’s clinical symptoms during 
the first hours of FN.
Mortality in patients with FN is therefore linked to 
suitable empirical antibiotic coverage, depending 
on the antimicrobial resistance profiles in various 
hospitals. Further studies are needed to evaluate the 
microbiological findings and the prevalence of local 
resistance profiles. This will enable institutions to 
determine the most appropriate empirical antibiotic 
therapy and to document atypical pathogens, such 
as those prevailing in tropical areas.
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